Antibiotics for Klebsiella and Enterobacter Infections
For community-acquired Klebsiella and Enterobacter infections of mild-to-moderate severity, use ertapenem, ceftriaxone plus metronidazole (if anaerobic coverage needed), or piperacillin-tazobactam; for severe community-acquired or healthcare-associated infections, use carbapenems (meropenem, imipenem-cilastatin, or doripenem) as first-line therapy. 1
Community-Acquired Infections
Mild-to-Moderate Severity
For community-acquired intra-abdominal or urinary infections caused by Klebsiella or Enterobacter species:
Preferred regimens 1:
- Ertapenem 1 g IV every 24 hours
- Ceftriaxone 1-2 g IV every 12-24 hours (± metronidazole 500 mg every 8-12 hours if anaerobic coverage needed)
- Piperacillin-tazobactam 3.375 g IV every 6 hours
- Moxifloxacin 400 mg IV every 24 hours (only if local E. coli susceptibility ≥90%) 1
Avoid ampicillin-sulbactam due to high resistance rates among community-acquired E. coli, which often predicts cross-resistance patterns in Enterobacteriaceae 1.
High-Severity Community-Acquired Infections
For patients with APACHE II scores ≥15, immunosuppression, or significant comorbidities 1:
Preferred carbapenems 1:
- Meropenem 1 g IV every 8 hours
- Imipenem-cilastatin 500 mg IV every 6 hours or 1 g every 8 hours
- Doripenem 500 mg IV every 8 hours
Alternative regimens 1:
- Piperacillin-tazobactam 3.375 g IV every 6 hours (or 4.5 g every 6 hours for severe infections)
- Cefepime 2 g IV every 8-12 hours plus metronidazole 500 mg every 6 hours
- Levofloxacin 750 mg IV every 24 hours plus metronidazole (only if quinolone resistance <10% locally) 1
Healthcare-Associated and Multidrug-Resistant Infections
ESBL-Producing Klebsiella/Enterobacter
Carbapenems remain the gold standard for ESBL-producing Enterobacteriaceae 2, 3:
- Meropenem 1 g IV every 8 hours (preferred)
- Imipenem-cilastatin/relebactam 1.25 g IV every 6 hours 2
- Ertapenem 1 g IV every 24 hours (for non-critically ill patients)
Carbapenem-sparing alternatives (if organism susceptible) 4, 5:
- Fluoroquinolones (ciprofloxacin 400 mg IV every 12 hours or levofloxacin 750 mg IV every 24 hours) can be considered if in vitro susceptibility confirmed, though carbapenems show superior outcomes 4
- Piperacillin-tazobactam may be used for susceptible ESBL strains, though clinical data are mixed 5
Carbapenem-Resistant Enterobacteriaceae (CRE)
For KPC-producing Klebsiella 2, 6, 7:
- Meropenem-vaborbactam 4 g IV every 8 hours (first-line choice) 7
- Imipenem-cilastatin/relebactam 1.25 g IV every 6 hours (alternative for KPC) 2, 6
- Ceftazidime-avibactam 2.5 g IV every 8 hours (if KPC-producing and ceftazidime-avibactam susceptible) 2
For OXA-48-like producing organisms 6, 8:
- Ceftazidime-avibactam 2.5 g IV every 8 hours (preferred) 6, 8
- Consider adding to standard therapy rather than monotherapy for improved outcomes 8
For metallo-β-lactamase (MBL) producers 6, 3:
- Ceftazidime-avibactam 2.5 g IV every 8 hours plus aztreonam 1-2 g IV every 6-8 hours 2, 6
- Cefiderocol (alternative for MBL-producing organisms) 6
Salvage options for extensively resistant CRE 2:
- Colistin 5 mg CBA/kg IV loading dose, then 2.5 mg CBA × (1.5 × CrCl + 30) IV every 12 hours plus tigecycline 100 mg IV loading, then 50 mg IV every 12 hours
- Polymyxin-based combinations with meropenem (extended infusion) or tigecycline 2
Critical Considerations
Susceptibility testing is mandatory for Klebsiella, Enterobacter, and other Enterobacteriaceae, as these organisms frequently harbor resistance mechanisms 1. Extended-infusion meropenem (over 3 hours) should be considered when MIC ≥8 mg/L 2.
Enterococcal coverage is NOT routinely needed for community-acquired infections 1, but should be added for healthcare-associated infections, particularly in postoperative patients, those with prior cephalosporin exposure, immunocompromised patients, or those with valvular heart disease 1.
Aminoglycosides are not recommended for routine empiric therapy in adults due to toxicity, though they may be added for severe infections with documented resistant organisms 1.
Duration of therapy: 5-7 days for uncomplicated urinary tract infections and intra-abdominal infections with adequate source control; 10-14 days for bloodstream infections; individualize based on clinical response 2.